AP3546A - Amides of 2-amino-4-arylthiazole compounds and their salts - Google Patents

Amides of 2-amino-4-arylthiazole compounds and their salts

Info

Publication number
AP3546A
AP3546A AP2014008076A AP2014008076A AP3546A AP 3546 A AP3546 A AP 3546A AP 2014008076 A AP2014008076 A AP 2014008076A AP 2014008076 A AP2014008076 A AP 2014008076A AP 3546 A AP3546 A AP 3546A
Authority
AP
ARIPO
Prior art keywords
amides
salts
amino
arylthiazole compounds
arylthiazole
Prior art date
Application number
AP2014008076A
Other languages
English (en)
Other versions
AP2014008076A0 (en
Inventor
Suresh Mahadev Kadam
Abraham Thomas
Sukumar Sinha
Sukeerthi Kumar
Bipin Parsottam Kansagra
Sachin Gavhane
Sandeep Bandu Khandagale
Shailesh Pawase
Jayant Prakashrao Patil
Shailendra Bhadane
Bhavna Mishra
Rajesh Dwivedi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3546(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of AP2014008076A0 publication Critical patent/AP2014008076A0/xx
Application granted granted Critical
Publication of AP3546A publication Critical patent/AP3546A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AP2014008076A 2012-06-08 2013-06-08 Amides of 2-amino-4-arylthiazole compounds and their salts AP3546A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1687MU2012 2012-06-08
US201261665282P 2012-06-27 2012-06-27
IN3519MU2012 2012-12-13
US201261748016P 2012-12-31 2012-12-31
PCT/IB2013/054703 WO2013183035A2 (en) 2012-06-08 2013-06-08 Amides of 2-amino-4-arylthiazole compounds and their salts

Publications (2)

Publication Number Publication Date
AP2014008076A0 AP2014008076A0 (en) 2014-11-30
AP3546A true AP3546A (en) 2016-01-14

Family

ID=54193746

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014008076A AP3546A (en) 2012-06-08 2013-06-08 Amides of 2-amino-4-arylthiazole compounds and their salts

Country Status (22)

Country Link
US (1) US9458173B2 (es)
EP (1) EP2858999B1 (es)
JP (1) JP5989900B2 (es)
KR (1) KR20150015488A (es)
CN (1) CN104350058A (es)
AP (1) AP3546A (es)
AU (1) AU2013273118B2 (es)
BR (1) BR112014029155A2 (es)
CA (1) CA2873570C (es)
CL (1) CL2014003317A1 (es)
EA (1) EA031334B1 (es)
HK (1) HK1207643A1 (es)
IL (1) IL236084A0 (es)
IN (1) IN2014MN02467A (es)
MX (1) MX354014B (es)
MY (1) MY165622A (es)
NZ (1) NZ701721A (es)
PE (1) PE20142306A1 (es)
PH (1) PH12014502685A1 (es)
SG (1) SG11201408093PA (es)
WO (1) WO2013183035A2 (es)
ZA (1) ZA201500082B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
BR112014030630A2 (pt) 2012-06-08 2017-06-27 Gilead Sciences Inc inibidores macrocíclicos de vírus flaviviridae
BR112015030341A2 (pt) * 2013-06-20 2017-07-25 Glenmark Pharmaceuticals Sa formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície
WO2016023832A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
US20190175599A1 (en) * 2014-09-16 2019-06-13 Glemark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
TW202321229A (zh) 2021-08-18 2023-06-01 美商富曼西公司 殺真菌的取代的雜環化合物
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010109334A2 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Thienopyrimidinedione derivatives as trpa1 modulators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US6890923B2 (en) 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
WO2004055054A1 (en) 2002-12-18 2004-07-01 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical MERGED PYRIMIDINE DERIVATIVE AND USE THEREOF
US20070099940A1 (en) 2004-02-11 2007-05-03 Spearing Paul K Pth agonists
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
JPWO2006083005A1 (ja) 2005-02-03 2008-06-26 武田薬品工業株式会社 縮合ピリミジン誘導体およびその用途
AU2006278592A1 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
US20070105920A1 (en) 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
CA2634152A1 (en) 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
CN101454318A (zh) * 2006-03-22 2009-06-10 阿斯利康(瑞典)有限公司 吡啶并嘧啶衍生物及其作为pde4抑制剂的用途
JP2011201776A (ja) 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−n−(3,4−ジヒドロ−2(1h)−キナゾリノン−5−イル)アセトアミド誘導体
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
WO2009002933A1 (en) * 2007-06-22 2008-12-31 Hydra Biosciences, Inc. Methods and compositions for treating disorders
WO2010004390A1 (en) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
KR20120001746A (ko) 2009-03-23 2012-01-04 그렌마크 파머수티칼스 에스. 아. Trpa1 조절자로서 이소티아졸로-피리미딘디온 유도체
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
KR20110132575A (ko) 2009-03-23 2011-12-08 그렌마크 파머수티칼스 에스. 아. Trpa1 조절자로서 융합된 피리미딘디온 유도체
MY159059A (en) 2010-12-20 2016-12-15 Glenmark Pharmaceuticals Sa 2-amino-4-arylthiazole compounds as trpa1 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010109334A2 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Thienopyrimidinedione derivatives as trpa1 modulators
WO2010109329A1 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators

Also Published As

Publication number Publication date
WO2013183035A3 (en) 2014-02-27
PH12014502685B1 (en) 2015-01-26
US20150111038A1 (en) 2015-04-23
BR112014029155A2 (pt) 2017-06-27
EA031334B1 (ru) 2018-12-28
AP2014008076A0 (en) 2014-11-30
IL236084A0 (en) 2015-02-01
EP2858999A2 (en) 2015-04-15
EP2858999B1 (en) 2017-05-10
CN104350058A (zh) 2015-02-11
NZ701721A (en) 2016-03-31
JP2015520183A (ja) 2015-07-16
WO2013183035A2 (en) 2013-12-12
MX2014014482A (es) 2015-06-05
JP5989900B2 (ja) 2016-09-07
AU2013273118A1 (en) 2014-11-27
CL2014003317A1 (es) 2015-02-13
PE20142306A1 (es) 2015-01-16
MX354014B (es) 2018-02-08
AU2013273118B2 (en) 2015-11-05
US9458173B2 (en) 2016-10-04
PH12014502685A1 (en) 2015-01-26
MY165622A (en) 2018-04-18
CA2873570A1 (en) 2013-12-12
IN2014MN02467A (es) 2015-07-10
SG11201408093PA (en) 2015-01-29
EA201492054A1 (ru) 2016-08-31
ZA201500082B (en) 2015-12-23
KR20150015488A (ko) 2015-02-10
HK1207643A1 (en) 2016-02-05
CA2873570C (en) 2016-11-01

Similar Documents

Publication Publication Date Title
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
ZA201502503B (en) Hppd variants and methods of use
HUE044300T2 (hu) 3-amino-cikloalkil-vegyületek, mint ROR-GAMMA-T inhibitorok és alkalmazásuk
EP2938341A4 (en) Heterocyclic compounds and methods for the use thereof
ZA201406082B (en) Use of ccr3-inhibitors
HK1207643A1 (en) Amides of 2-amino-4-arylthiazole compounds and their salts 2--4-
AP3611A (en) Heterocyclic compounds and their uses
EP2938607A4 (en) CRYSTALLINE SALTS AND FORMS
EP2881113A4 (en) NEW APPLICATION OF POGOSTONE
EP2935227A4 (en) DIAZOLAMIDE
HK1210168A1 (en) Amine salt and crystals thereof